Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Jacobsen

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Blood|December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL ConsortiumMark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Annals of Hematology|July 25, 2021
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyWon Seog Kim, Yasuhiro Oki, Seok Jin Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Blood|December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL ConsortiumMark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Annals of Hematology|July 25, 2021
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyWon Seog Kim, Yasuhiro Oki, Seok Jin Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
Pageof 5